Alpha Tau and Samsung Medical Center Sign MOU to Explore Clinical Trial of Alpha DaRT® for Pancreatic Cancer Patients in Korea

Adding South Korea could potentially extend Alpha Tau’s pancreatic cancer program to six countries.

Rhea-AI Summary

Alpha Tau Medical (Nasdaq: DRTS) signed a memorandum of understanding with Samsung Medical Center to explore a pancreatic cancer trial in South Korea.

The potential study at the Seoul hospital would be Alpha DaRT’s first clinical trial in South Korea. Any trial remains subject to regulatory and ethics committee approvals; the agreement concerns exploring a study rather than starting one. Alpha Tau said adding Korea could potentially extend its pancreatic cancer program to six countries across North America, Europe, the Middle East and Asia.

Alpha DaRT is an investigational radiation treatment designed to deliver radium-224 sources directly into solid tumors. Samsung Medical Center plans to review the treatment’s clinical application under the exploratory collaboration.

2 points · 0 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 2 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Moderate pointSigned MOU with Samsung Medical Center advances exploration of Alpha DaRT’s first clinical trial in South Korea.
• Minor point. Forward-looking: it has not happened yet and may not happen.Pancreatic cancer program could potentially span six countries with Korea, Alpha Tau said.

Negative

• Moderate pointExploratory MOU concerns a potential clinical trial, not an agreement to begin one.
• Minor point. Forward-looking: it has not happened yet and may not happen.Regulatory and ethics committee approvals would be required for any trial.

Previous Clinical trial Reports

3 past events · Latest: Apr 23

Same Type 3 events

1. Apr 23

   Pancreatic trial treatment

   24h Move

   -1.2%

   First European pancreatic cancer patient treated in the ACAPELLA trial.

2. Sep 02

   Pancreatic trial treatment

   24h Move

   +1.8%

   First U.S. patient treated in the IMPACT pancreatic cancer pilot study.

3. Jan 27

   Pancreatic trial data

   24h Move

   +4.2%

   Pancreatic trials reported delivery success, objective response, and disease control results.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

intratumoral delivery, radium-224, relative survival rate, pancreatectomies

4 terms

intratumoral delivery medical

"by intratumoral delivery of radium-224 impregnated sources"

A method of giving a medicine or therapeutic agent directly into a solid tumor, rather than into the bloodstream, to concentrate the treatment where cancer is located. Like putting a watering can on the plant instead of spraying the whole garden, it can increase local effectiveness and reduce side effects elsewhere in the body, which matters to investors because it can influence clinical success, safety profiles, regulatory approval chances and commercial value.

radium-224 technical

"delivery of radium-224 impregnated sources"

A radioactive isotope of the element radium (atomic number 88) that emits alpha particles as it decays. Radium-224 has a short half‑life of about 3.6 days and decays through a chain that includes the noble gas radon-220 (thoron). In medical and regulatory contexts it is treated as a controlled radioactive material used in certain radiopharmaceutical research and targeted radiation therapies or as a source in industrial/radiation applications; handling, transport and clinical use are subject to radiation‑safety rules and licensing. Its properties and uses are distinct from other radium isotopes (for example radium-223).

relative survival rate medical

"its five-year relative survival rate of 17.0%"

Relative survival rate measures how long a group of patients with a disease live compared with people in the general population who are similar in age and sex. Think of it as the disease group's survival divided by the expected survival if they did not have the disease; it helps isolate the effect of the illness or treatment. Investors use it to judge a therapy’s real-world benefit and potential commercial value by showing whether a treatment meaningfully improves survival beyond normal expectations.

pancreatectomies medical

"performed more than 4,000 pancreatectomies for pancreatic cancer"

Surgical operations that remove part or all of the pancreas; they include procedures such as distal pancreatectomy (removing the body and tail), pancreaticoduodenectomy (Whipple procedure, removing the head and sometimes nearby structures), and total pancreatectomy (removing the entire gland). Removing pancreatic tissue stops or reduces the organ’s production of digestive enzymes and insulin, so patients commonly develop exocrine insufficiency (requiring enzyme replacement) and/or diabetes (requiring insulin therapy), and the surgery carries the usual risks of major abdominal operations like bleeding, infection and delayed gastric emptying.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

- MOU relates to a potential clinical trial in South Korea, Alpha DaRT’s first, at Samsung Medical Center (SMC) in Seoul, ranked fifth in the world and number one in Korea in oncology -

- In Korea, only about one in five pancreatic cancer patients undergo surgery, and the disease’s death rate rose over 6% in 2025, the steepest increase among major cancers -

JERUSALEM, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT^®, today announced the signing of an MOU in Seoul, South Korea, with Samsung Medical Center (SMC), regarding a potential clinical trial in pancreatic cancer patients. Any such trial would be subject to regulatory and ethics committee approvals.

Pancreatic cancer is one of Korea’s deadliest cancers. It is now the country’s fourth leading cause of cancer death, and unlike most cancers in Korea, its death rate has continued to rise. In 2023, 9,748 Koreans were diagnosed with the disease, and its five-year relative survival rate of 17.0% is the lowest of any cancer in the country. Fewer than one in six patients are diagnosed while the cancer is still confined to the pancreas, and more than four in ten are diagnosed only after it has already spread to distant organs.

SMC is ranked fifth in the world and number one in Korea in oncology. Its Pancreatobiliary Cancer Center combines a multidisciplinary team, a fast-track pathway for diagnosis and treatment, and a high-volume surgical program that has performed more than 4,000 pancreatectomies for pancreatic cancer between 2008 and 2025.(Courtesy of SMC)

Uzi Sofer, CEO of Alpha Tau, stated: “Signing this MOU with Samsung Medical Center, one of the world’s leading medical centers, is an important step forward in our goal to bring Alpha DaRT to cancer patients wherever they are. With Korea, our pancreatic cancer program could potentially span six countries across North America, Europe, the Middle East and Asia. I am grateful for SMC’s confidence in Alpha Tau and for the opportunity to explore the potential of Alpha DaRT to benefit its patients.”

Hee-Chul Kim, EVP of Samsung Medical Center, General Director of Samsung Comprehensive Cancer Center (SCCC), stated: “Pancreatic cancer remains one of the most challenging cancers to treat, and treatment options are limited for many patients. We hope this MOU will help us explore new possibilities for these patients. We will carefully review the clinical application of Alpha DaRT and do our best to strengthen our own research capabilities.”

About Alpha Tau Medical Ltd.

Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company focused on the research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.

About Alpha DaRT^®

Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to primarily affect the tumor and to spare healthy tissue surrounding it.

About Samsung Comprehensive Cancer Center

Samsung Comprehensive Cancer Center (SCCC) is guided by respect for life, striving for excellence in patient care, research, and education to help people lead healthier, happier lives. Since opening in 2008 as Korea’s first and largest cancer center of its kind, SCCC has continued to expand its capabilities, establishing the Supportive Care Center (2014), the Proton Therapy Center (2016), the CAR T-Cell Therapy Center (2021), and the Precision Oncology Therapeutics Center (2022). In 2023, SCCC signed MOUs with Gustave Roussy and Charité to strengthen its global collaboration, and in 2024 it opened the Institute for Quality of Life in Cancer. In 2026, SCCC achieved ICHOM Level 1 accreditation and signed an MOU with EORTC. SMC was ranked fifth in the world and first in Korea in oncology in Newsweek’s World’s Best Specialized Hospitals 2027.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. When used herein, words including “anticipate,” “will,” “plan,” “may,” “continue,” and similar expressions are intended to identify forward-looking statements. Other than its marketing approval in Japan for unresectable locally advanced or locally recurrent head and neck cancer, the Alpha DaRT treatment has not been approved for commercialization or for use outside of an approved clinical trial. In addition, any statements or information that refer to the Alpha DaRT treatment in pancreatic cancer patients, including a potential collaboration with Samsung Medical Center, the planned clinical trial in Korea and the timing of the required regulatory and ethics committee approvals, the potential benefits and associated risks, safety, feasibility and efficacy, future applications and uses, and other expectations, beliefs and plans, including with respect to clinical trials, regulatory approvals and studies, are forward-looking. All forward-looking statements are based upon Alpha Tau’s current expectations and various assumptions. Alpha Tau believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Alpha Tau may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation: (i) Alpha Tau’s ability to receive regulatory approval for its Alpha DaRT technology or any future products or product candidates; (ii) Alpha Tau’s limited operating history; (iii) Alpha Tau’s incurrence of significant losses to date; (iv) Alpha Tau’s need for additional funding and ability to raise capital when needed; (v) Alpha Tau’s limited experience in medical device discovery and development; (vi) Alpha Tau’s dependence on the success and commercialization of the Alpha DaRT technology; (vii) the failure of preliminary data from Alpha Tau’s clinical studies to predict final study results; (viii) failure of Alpha Tau’s early clinical studies or preclinical studies to predict future clinical studies; (ix) Alpha Tau’s ability to enroll patients in its clinical trials; (x) undesirable side effects caused by Alpha Tau’s Alpha DaRT technology or any future products or product candidates; (xi) Alpha Tau’s exposure to patent infringement lawsuits; (xii) Alpha Tau’s ability to comply with the extensive regulations applicable to it; (xiii) the ability to meet Nasdaq’s listing standards; (xiv) costs related to being a public company; (xv) changes in applicable laws or regulations; and the other important factors discussed under the caption “Risk Factors” in Alpha Tau’s annual report filed on form 20-F with the SEC on March 9, 2026, and other filings that Alpha Tau may make with the United States Securities and Exchange Commission. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While Alpha Tau may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing Alpha Tau’s views as of any date subsequent to the date of this press release.

Investor Relations Contact:

IR@alphatau.com

Samsung Medical Center Media Contact:

Su-sung Kim, Team Leader, Communications Team, Samsung Medical Center, +82-2-3410-3042,

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Alpha Tau’s agreement with Samsung Medical Center cover?

The memorandum of understanding covers exploration of a potential Alpha DaRT clinical trial for pancreatic cancer patients in South Korea. The study would be Alpha DaRT’s first clinical trial in the country and would require regulatory and ethics committee approvals.